News: Simtuzumab

We provide the latest news and info on Simtuzumab


Bidness Etc
Intercept Could Soon Be The Market Leader For Obesity Treatment
Bidness Etc
Gilead's monoclonal antibody, Simtuzumab, has reached the second phase of trials, while Novo Nordisk's weight loss medication, Victoza, is awaiting FDA approval. A big advantage for Intercept will be the high pricing it can assign to its first-in-class ...

and more »

Published on Monday 18th of August 2014 02:57:14 AM Read more...

2 Healthcare Stocks That Appear To Trade Below Fair Value Estimates
Seeking Alpha (registration)
... years with patent expirations and increased competition in the burgeoning HCV marketplace, Gilead's extensive pipeline into HIV, liver diseases, and orphan conditions like idiopathic pulmonary fibrosis (e.g., simtuzumab, a LOXL2 inhibitor that ...

Published on Monday 18th of August 2014 02:57:14 AM Read more...

Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic
MarketWatch
Gilead is acting across a broader age spectrum in NASH treatment and should be completing enrollment soon for a Phase 2b testing of its drug simtuzumab (GS-6624). Results might be announced late 2016 or so. Gilead is looking to grow its footprint in ...

and more »

Published on Monday 18th of August 2014 02:57:14 AM Read more...

Gilead Sciences Q2 2014: All Is Good, More To Come At Medical Conferences ...
Seeking Alpha (registration)
Extremely important Pipeline data for oncology pipeline coming by year end with simtuzumab, pending data results will determine rapidity of an acquisition of MGNX and a "go/no-go" for a INCY acquisition. Congressional and Payor criticism of Sovaldi's ...

and more »

Published on Monday 18th of August 2014 02:57:14 AM Read more...

Gilead Is Going To Make More Money In The Future
Seeking Alpha (registration)
In addition to the ph3 trials for GS-5816 pan-GT HCV regimens and 4-6 week readouts, we think the potential impact of simtuzumab ("S-Mab") and TAF is underappreciated at the current multiple (9.3x our new 2015 EPS). We specifically look for signals in ...

and more »

Published on Monday 18th of August 2014 02:57:14 AM Read more...

Gilead Sciences (GILD) PT Lifted to $165 at BMO Capital on Strong Q2
StreetInsider.com (subscription)
Beyond the anti-viral franchise, approval of ZELDIG and an expanding pipeline of fast-follower drugs such as JAK2 inhibitor momelotinib as well as first-in-class drugs such as anti-fibrotic simtuzumab provide significant upside potential, in our view.".

Published on Monday 18th of August 2014 02:57:14 AM Read more...

Genfit : Galectin, un concurrent de moins dans la NASH ?
Trading Sat
... des résultats d'efficacité très convaincants (mais accompagnés de certaines réserves sur la sécurité), tandis que Gilead devrait dévoiler en mai 2016 les résultats de son étude de phase 2B dans la NASH avec son médicament expérimental Simtuzumab.

and more »

Published on Monday 18th of August 2014 02:57:14 AM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts